Literature DB >> 9529293

Intravenous and intra-arterial oxygen-15-labeled water and fluorine-18-labeled fluorouracil in patients with liver metastases from colorectal carcinoma.

A Dimitrakopoulou-Strauss1, L G Strauss, P Schlag, P Hohenberger, G Irngartinger, F Oberdorfer, J Doll, G van Kaick.   

Abstract

UNLABELLED: Intra-arterial chemotherapy can potentially increase drug delivery at the tumor sites and has therefore been used for the therapy of metastatic colorectal cancer.
METHODS: Dynamic PET and [18F]fluorouracil (18F-FU) were used in patients with liver metastases from colorectal cancer to examine the pharmacokinetics of the drug up to 120 min after intravenous and intra-arterial injection of the same dose of fluorouracil (FU). All patients included in the study (n = 15) had surgically implanted catheters in the gastroduodenal artery. Dynamic PET studies (up to 5 min) with 15O-labeled water were performed for the evaluation of the access to the lesions immediately before the 18F-FU study using both administration routes. The final evaluation included 24 metastases, obtained from 15 patients.
RESULTS: Of 24 lesions, 21 (87.5%) showed an improved access using the intra-arterial approach, and 20 (83.3%) demonstrated a better FU influx after intra-arterial 18F-FU infusion. Metastases reached the highest 18F-FU concentrations after intra-arterial administration, with a maximum standardized uptake values of 18.75 for the FU influx and of 5.03 for FU trapping. Of 24 metastases, eight (33.3%) demonstrated enhanced FU trapping after the intra-arterial administration. Cluster analysis revealed a group of metastases (n = 6) with a nonperfusion-dependent FU transport using the intravenous application. Of these six lesions, five (83.3%) did not show any enhancement of the 18F-FU trapping after intra-arterial application. The data gave evidence for at least one different, energy-dependent transport system, which can be saturated even after intravenous administration of the drug.
CONCLUSION: The data show that the main limiting factor for a therapy response is the very high and rapid elimination of the cytostatic agent out of the tumor cells. Furthermore, it was not possible to predict the pharmacokinetics of FU after intra-arterial application using an intravenous PET study. It may be possible, using intravenous PET double-tracer studies, to identify metastases having a nonperfusion-dependent transport system and exclude them from an intra-arterial treatment protocol.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9529293

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  5 in total

Review 1.  Positron emission tomography (PET): expanding the horizons of oncology drug development.

Authors:  Lisa A Hammond; Louis Denis; Umber Salman; Paul Jerabek; Charles R Thomas; John G Kuhn
Journal:  Invest New Drugs       Date:  2003-08       Impact factor: 3.850

Review 2.  Use of positron emission tomography in anticancer drug development.

Authors:  Eric O Aboagye; Patricia M Price
Journal:  Invest New Drugs       Date:  2003-05       Impact factor: 3.850

Review 3.  Development of radiotracers for oncology--the interface with pharmacology.

Authors:  Rohini Sharma; Eric Aboagye
Journal:  Br J Pharmacol       Date:  2011-08       Impact factor: 8.739

4.  Continuous angiotensin II infusion increases tumour: normal blood flow ratio in colo-rectal liver metastases.

Authors:  D Burke; M M Davies; J Zweit; M A Flower; R J Ott; M J Dworkin; C Glover; V R McCready; P Carnochan; T G Allen-Mersh
Journal:  Br J Cancer       Date:  2001-11-30       Impact factor: 7.640

5.  A Transmetalation Reaction Enables the Synthesis of [18F]5-Fluorouracil from [18F]Fluoride for Human PET Imaging.

Authors:  Andrew J Hoover; Mark Lazari; Hong Ren; Maruthi Kumar Narayanam; Jennifer M Murphy; R Michael van Dam; Jacob M Hooker; Tobias Ritter
Journal:  Organometallics       Date:  2016-02-14       Impact factor: 3.876

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.